Hypertension and IOP linked

Article

Increased blood pressure contributes to elevated IOP and possibly the development of glaucoma, according to the findings of a recent meta-analysis.

Increased blood pressure contributes to elevated IOP and possibly the development of glaucoma, according to the findings of a meta-analysis published by the American Journal of Ophthalmology.

The researchers, from the US and South Korea, conducted a systematic review of 60 observational studies identified through a search of the PubMed and EMBASE databases. They summarized relative risks using inverse-variance weighted random-effects models, and they analysed subgroups and performed meta-regression to look for similarities among the studies.

Comparing those with and without hypertension, the investigators found a pooled relative risk for primary open-angle glaucoma of 1.16. Almost all of the studies demonstrated a positive association between blood pressure and IOP. When systolic blood pressure increased 10 mmHg, IOP increased 0.26 mmHg, based on pooled averages. When diastolic blood pressure increased 5 mmHg, IOP increased an average of 0.17 mmHg.

To view an abstract of the study, click here.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.